Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA02 - RET and Novel Combinations of Osimertinib
- 09:30 - 10:30
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
-
+
MA02.08 - Discussant
10:15 - 10:30 | Presenter: Adrian G. Sacher
- Abstract
No abstract available for this presentation
-
+
FP01 - Early Stage/Localized Disease/Ablative Therapies
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
FP01.03 - Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
00:00 - 00:00 | Presenter: Sabine Schmid
- Abstract
Loading...
-
+
FP05 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
-
+
FP05.02 - A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer
00:00 - 00:00 | Presenter: Valsamo Anagnostou
- Abstract
Loading...
-
+
FP12 - Predictive Tumor Based Assays/Biomarkers/Pathology
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
FP12.01 - PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
00:00 - 00:00 | Presenter: Sally CM Lau
- Abstract
Loading... -
+
FP12.07 - Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients
00:00 - 00:00 | Presenter: Joshua E Herman
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P45.05 - Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival
00:00 - 00:00 | Presenter: Sally CM Lau
- Abstract
Loading... -
+
P45.07 - Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC
00:00 - 00:00 | Presenter: Sabine Schmid
- Abstract
Loading... -
+
P45.09 - Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
00:00 - 00:00 | Presenter: Simren Chotai
- Abstract
Loading...
-
+
P48 - Novel Therapeutics and Targeted Therapies - EGFR
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P48.05 - Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
00:00 - 00:00 | Presenter: Miguel Garcia
- Abstract
Loading...
-
+
P59 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Targeted Therapies Biomarkers
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
P59.17 - EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients
00:00 - 00:00 | Presenter: Preet Walia
- Abstract
Loading...
-
+
OA08 - Moving Beyond New Drugs: What Else Matters?
- 09:30 - 10:30
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Health Services Research/Health Economics
- Moderators:Upal Basu Roy
-
+
OA08.04 - Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population
10:00 - 10:10 | Presenter: Marie-pier Gauthier
- Abstract
Loading...
-
+
MA08 - Driver Mutations and Immune Profiles in Early Stage NSCLC
- 12:00 - 13:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
MA08.02 - Outcomes of Early Stage ALK-positive NSCLC Patients in a Real-World Cohort
12:05 - 12:10 | Presenter: Sabine Schmid
- Abstract
Loading...
-
+
MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC
- 18:45 - 19:45
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
MA14.03 - Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib
18:55 - 19:00 | Presenter: Ferdinandos Skoulidis
- Abstract
Loading...